Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

The study evaluated the long-term efficacy of ritlecitinib in patients aged ≥12 years with alopecia areata (AA) and ≥50% scalp hair loss over 24 months. In the ALLEGRO-2b/3 and ALLEGRO-LT trials, 385 patients were divided into two groups: one receiving a 200-mg loading dose followed by 50 mg daily, and the other receiving 50 mg daily without a loading dose. Results showed that the proportion of patients achieving a SALT score ≤20 increased from Month 12 to Month 24 in both groups, with sustained response rates of 92.8% and 79.7% for the 200/50-mg and 50-mg groups, respectively. Patient-reported improvements were also maintained. These findings support the long-term use of ritlecitinib for treating severe AA.